Doris Apt from 1160 El Abra Way, San Jose, CA 95125, age 75

Resumes

Doris Apt

view source

Us Patents

Recombinant Dengue Virus Antigens Comprising The C15 Signal Peptide, Full-Length Prm Protein, And Full-Length E Protein
view source
US Patent:

8158131, Apr 17, 2012
Filed:

Mar 7, 2008
Appl. No.:

12/075097
Inventors:

Doris Apt - San Jose CA, US
Juha Punnonen - Belmont CA, US
Alice M. Brinkman - Tustin CA, US
Assignee:

AltraVax, Inc. - Fargo ND
International Classification:

A61K 39/12
A61K 39/00
US Classification:

4242181, 4241921
Abstract:

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.

Nucleic Acids Encoding Novel Chimeric C15/Prm/E Dengue Virus Immunogens Prepared By Dna Shuffling
view source
US Patent:

8168772, May 1, 2012
Filed:

Aug 30, 2007
Appl. No.:

11/897320
Inventors:

Doris Apt - San Jose CA, US
Juha Punnonen - Belmont CA, US
Alice M. Brinkman - Tustin CA, US
Assignee:

Altravax, Inc. - Fargo ND
International Classification:

C07H 21/04
A61K 39/12
A61K 39/295
A61K 39/00
US Classification:

536 2372, 4242181, 4241921, 4242021, 435 691
Abstract:

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.

Novel Co-Stimulatory Molecules
view source
US Patent:

20030138881, Jul 24, 2003
Filed:

Dec 20, 2001
Appl. No.:

10/032214
Inventors:

Juha Punnonen - Belmont CA, US
Alexandra Lazetic - San Jose CA, US
Steven Leong - Berkeley CA, US
Chia-Chun Chang - Los Gatos CA, US
Doris Apt - Sunnyvale CA, US
Claes Gustafsson - Belmont CA, US
Assignee:

Maxygen, Inc. - Redwood City CA
International Classification:

C07K014/705
C12P021/02
C12N005/06
C07H021/04
US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.

Novel Co-Stimulatory Molecules
view source
US Patent:

20030190697, Oct 9, 2003
Filed:

Jun 22, 2001
Appl. No.:

09/888324
Inventors:

Juha Punnonen - Belmont CA, US
Alexandra Lazetic - San Jose CA, US
Steven Leong - Berkeley CA, US
Chia-Chun Chang - Los Gatos CA, US
Doris Apt - Sunnyvale CA, US
Claes Gustafsson - Belmont CA, US
International Classification:

C12P021/02
C12N005/06
C07K014/705
C07H021/04
US Classification:

435/069100, 435/320100, 435/325000, 530/350000, 536/023500
Abstract:

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.

Nucleic Acid Vectors
view source
US Patent:

20040110295, Jun 10, 2004
Filed:

May 28, 2003
Appl. No.:

10/446629
Inventors:

Juha Punnonen - Belmont CA, US
Doris Apt - Sunnyvale CA, US
Robert Whalen - Foster City CA, US
Assignee:

Maxygen, Inc., a Delaware corporation - Redwood City CA
International Classification:

C12Q001/68
C07H021/04
C12N015/85
US Classification:

435/455000, 435/006000, 435/320100, 536/023100
Abstract:

The invention relates to nucleic acid vectors useful for expression and production of polypeptides, compositions comprising vectors, and methods for the production and use of vectors and polypeptides.

Novel Tumor-Associated Antigens
view source
US Patent:

20050084913, Apr 21, 2005
Filed:

Apr 19, 2004
Appl. No.:

10/828559
Inventors:

Juha Punnonen - Belmont CA, US
Doris Apt - San Jose CA, US
Margaret Neighbors - San Jose CA, US
Steven Leong - Berkeley CA, US
International Classification:

C12Q001/68
G01N033/53
G01N033/567
C07K016/28
US Classification:

435007200, 530388220
Abstract:

The invention provides novel polypeptides, including novel tumor-associated antigens, and related nucleic acids, vectors, cells, and antibodies. The invention also provides compositions comprising such polypeptides, nucleic acids, vectors, cells, and antibodies, and methods of producing and using the same.

Novel Co-Stimulatory Molecules
view source
US Patent:

20050154189, Jul 14, 2005
Filed:

Jun 21, 2002
Appl. No.:

10/479901
Inventors:

Juha Punnonen - Belmont CA, US
Alexandra Lazetic - San Jose CA, US
Steven Leong - Berkeley CA, US
Jean Chang - Los Gatos CA, US
Doris Apt - Sunnyvale CA, US
Claes Gustafsson - Belmont CA, US
International Classification:

C07K014/74
C07K016/28
US Classification:

530350000, 530388220
Abstract:

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a human CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind human CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.

Novel Co-Stimulatory Molecules
view source
US Patent:

20060269566, Nov 30, 2006
Filed:

Jan 13, 2006
Appl. No.:

11/332037
Inventors:

Juha Punnonen - Belmont CA, US
Alexandra Lazetic - San Jose CA, US
Steven Leong - Berkeley CA, US
Chia-Chun Chang - Los Gatos CA, US
Doris Apt - Sunnyvale CA, US
Claes Gustafsson - Belmont CA, US
Assignee:

Maxygen, Inc. - Redwood City CA
International Classification:

C07K 14/74
C07H 21/04
C12P 21/06
A61K 39/00
US Classification:

424192100, 435069100, 435320100, 435325000, 530350000, 536023200
Abstract:

The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynucleotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.

Name / Title

Company / Classification

Phones & Addresses

Doris Apt
Senior Clinical Research Scientist

MAXYGEN, INC
Mfg of Pharmaceutical Preparations and Biotechnological Research Services · Pharmaceutical Preparations & Biotechnological Research · Pharmaceutical Preparations and Biotechnological Research · Research and Development in the Physical, Engineering, and L · Pharmaceutical Preparation Manufacturing · Research & Development in Biotechnology · Biotechnology Products & Servi

515 Galveston Dr, Redwood City, CA 94063
301 Galveston Dr, Redwood City, CA 94063
650 298-5300, 650 298-5399, 650 298-5885, 650 364-2715